Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Redeye R&D Conference 2020
10 slides from Arcticzymes Technologies Asa's conference presentation, Nov 10, 2020
Slide 1: ArcticZymes Technologies
ArcticZymes Technologies Shaped by the Arctic Jethro Holter, CEO Børge Sørvoll, CFO 10th November 2020
Slide 2: Specialist supplier of best-in-class novel enzymes
Specialist supplier of best-in-class novel enzymes Innovative Offering B2B and OEM sales Performance • Novel enzymes technology • Broad customer base and long- • Profitable & sales rapidly growing • Focus on high-quality, robust term commercial relationships • Forward leaning growth strategy manufac
Slide 3: Our Novel Enzyme Products
Our Novel Enzyme Products Different ways in which enzymes can manipulate DNA, for example: Therapeutics Molecular Diagnostics Gene therapy & DNA vaccines Viral Based Diagnostics • Optimal solution • Faster sample-to-answer • Streamlines workflow • Workflow simplified • Cost effective • Supports simp
Slide 4: Target Markets & Customers
Target Markets & Customers Serving attractive & growing markets 40 Therapeutics Gene therapy & DNA 30 vaccine manufacturers CAGR (%) Molecular Research 20 Research kit manufacturers Molecular Diagnostics 10 Commercial diagnostic test developers 0 0 1 2 3 4 5 6 7 8 9 10 Market size Billion USD 4 [Sou
Slide 5: Our Customers
Our Customers ArcticZymes is a trusted critical raw material supply Our customer’ ArcticZymes Our Customers Customers Component Other Companies End Users supplier (B2B) (B2C) Our Business Dynamics • Large volume bulk sales (often >1MNOK orders) • Economies of scale achieve highest gross margins (>90
Slide 6: Delivering on growth & profitability
ArcticZymes Technologies Delivering on growth & profitability 50 Sales, Gross profit & EBITDA Sales 40 Gross profit Performance – First 9 Months 30 EBITDA NOK Millions Exceeded 100 MNOK in annual sales for first time > 20 102% growth 10 EBITDA: 51.1 MNOK (2019: -3.6 MNOK) Cash at period end: 69.7 MN
Slide 7: Growth Strategy
Growth Strategy European’s leading one-stop-shop enzyme supplier Simplified Workflow Value chain (Technology) Sanger Proteinase Reverse Transcriptases, Cod UNG, rSAP, Sequencing Polymerases Ligases, etc.. Next Generation Sequencing (NGS) Real time PCR/LAMP Cells DNA Amplified DNA Detection and Analy
Slide 8: Summary
Summary High Growth Accelerate Build Long-Term Business Expansion Shareholder Value About leverage existing Broaden product range: Driven by sustainable and new long-term B2B • Bolt and build via M&A profitablity and topline relationships • Ramp up innovation growth pipeline & operations 8
Slide 9: Thank you
A ArcticZymes Technologies
Slide 10: Disclaimer
Disclaimer This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking in
ArcticZymes Technologies — Redeye R&D Conference 2020 on 6ix